Acceleron Pharma Inc. (NASDAQ:XLRN) – Analysts at Oppenheimer Holdings boosted their Q3 2017 earnings per share estimates for shares of Acceleron Pharma in a research note issued on Thursday. Oppenheimer Holdings analyst L. Cann now anticipates that the biopharmaceutical company will post earnings of ($0.63) per share for the quarter, up from their prior estimate of ($0.67). Oppenheimer Holdings currently has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for Acceleron Pharma’s Q4 2017 earnings at ($0.53) EPS, FY2017 earnings at ($2.57) EPS, Q1 2018 earnings at ($0.56) EPS, Q2 2018 earnings at ($0.57) EPS, Q3 2018 earnings at ($0.56) EPS, Q4 2018 earnings at ($0.55) EPS, FY2018 earnings at ($2.24) EPS, FY2019 earnings at ($2.32) EPS, FY2020 earnings at ($1.89) EPS and FY2021 earnings at ($0.30) EPS.
A number of other brokerages have also issued reports on XLRN. Royal Bank Of Canada assumed coverage on Acceleron Pharma in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $44.00 target price on the stock. Barclays PLC lifted their target price on Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, September 20th. ValuEngine raised Acceleron Pharma from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Cann reissued a “hold” rating on shares of Acceleron Pharma in a research report on Tuesday, September 5th. Finally, UBS AG reissued a “buy” rating and issued a $50.00 target price (up previously from $36.00) on shares of Acceleron Pharma in a research report on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $42.81.
ILLEGAL ACTIVITY NOTICE: “Acceleron Pharma Inc. (XLRN) Forecasted to Post Q3 2017 Earnings of ($0.63) Per Share” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/10/11/acceleron-pharma-inc-xlrn-forecasted-to-post-q3-2017-earnings-of-0-63-per-share.html.
Acceleron Pharma (NASDAQ XLRN) opened at 39.49 on Monday. The company has a 50-day moving average price of $37.35 and a 200-day moving average price of $32.00. The firm’s market cap is $1.53 billion. Acceleron Pharma has a 12-month low of $23.07 and a 12-month high of $41.69.
Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.12). Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The firm had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.69 million. During the same quarter in the prior year, the company posted ($0.59) EPS. The company’s quarterly revenue was down 3.1% on a year-over-year basis.
Large investors have recently bought and sold shares of the business. Parametric Portfolio Associates LLC increased its holdings in shares of Acceleron Pharma by 3.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 9,456 shares of the biopharmaceutical company’s stock worth $287,000 after acquiring an additional 355 shares during the last quarter. TD Asset Management Inc. increased its holdings in shares of Acceleron Pharma by 0.8% during the 2nd quarter. TD Asset Management Inc. now owns 78,800 shares of the biopharmaceutical company’s stock worth $2,395,000 after acquiring an additional 600 shares during the last quarter. Tudor Investment Corp ET AL increased its holdings in shares of Acceleron Pharma by 8.5% during the 1st quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 716 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Acceleron Pharma by 9.7% during the 2nd quarter. Legal & General Group Plc now owns 10,470 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 923 shares during the last quarter. Finally, Teachers Advisors LLC increased its holdings in shares of Acceleron Pharma by 2.1% during the 1st quarter. Teachers Advisors LLC now owns 46,080 shares of the biopharmaceutical company’s stock worth $1,220,000 after acquiring an additional 942 shares during the last quarter. 77.35% of the stock is currently owned by hedge funds and other institutional investors.
In other Acceleron Pharma news, SVP John D. Quisel sold 5,113 shares of the business’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $38.42, for a total transaction of $196,441.46. Following the transaction, the senior vice president now owns 57,918 shares of the company’s stock, valued at approximately $2,225,209.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Corp /De/ Celgene purchased 745,592 shares of the stock in a transaction on Monday, September 25th. The shares were bought at an average cost of $37.00 per share, for a total transaction of $27,586,904.00. Following the transaction, the insider now directly owns 6,118,479 shares in the company, valued at $226,383,723. The disclosure for this purchase can be found here. Insiders have sold a total of 66,578 shares of company stock worth $2,518,117 in the last ninety days. Insiders own 3.90% of the company’s stock.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.